Video Review: Talking Biopolitics – A conversation with Paul Knoepfler and Nathaniel Comfort
By Dr. Rebecca Dimond,
BioNews
| 02. 01. 2016
Untitled Document
On 26 January 2016, the Center for Genetics and Society hosted an online discussion on 'Exploring heritable genetic modification: the promise and perils of altering future humans'. Paul Knoepfler, author of the 2015 book 'GMO Sapiens: The Life-Changing Science of Designer Babies', was interviewed by science historian Nathaniel Comfort.
I was looking forward to this webinar. The discussion was timely, following the passing of legislation on mitochondrial donation in the UK in 2015, and amid current debates about gene-editing technologies, such as CRISPR. Introducing the conversation, Marcy Darnovsky told the audience that genetic modification is 'now with us', a thought she described as both lively and sobering. Knoepfler's views about these developments are well known – during the UK mitochondrial donation debates, he contributed evidence to the scientific reviews, was mentioned at the House of Commons and House of Lords and hosts his own popular blog. He recently tweeted that he was 'excited about genetic modification' but was also cautious about 'talk of clinic use'.
Much of the conversation focused on the risks and benefits of...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...